Clonal hematopoiesis of indeterminate potential (CHIP) — age-related expansion of blood stem cells carrying preleukemic mutations — significantly increased death risk in 6,704 older women from the Women's Health Initiative. Large CHIP clones (variant allele frequency ≥10%) carried a 28% higher all-cause mortality risk, while any CHIP increased risk by 12%. Non-DNMT3A mutations drove most mortality risk, while DNMT3A mutations showed no significant association. Large CHIP specifically elevated cardiovascular death risk by 29%, cancer mortality by 49%, and neurologic death by 40%. This preprint represents one of the largest studies examining CHIP's mortality impact in older adults, adding crucial evidence to an emerging field. The findings suggest CHIP may serve as a novel biomarker for accelerated aging and multi-system disease risk. However, the study's observational design cannot establish causation, and results are limited to older women. The dose-response relationship between clone size and mortality risk supports biological plausibility, though mechanistic pathways remain unclear. As this research awaits peer review, these findings could reshape how we assess aging-related health risks and potentially guide early intervention strategies.